The utility of animal models in developing immunosuppressive agents

James McDaid, Christopher J. Scott, Adrien Kissenpfennig, Huifang Chen, Paulo N. Martins

Research output: Contribution to journalReview articlepeer-review

7 Citations (Scopus)
1265 Downloads (Pure)


The immune system comprises an integrated network of cellular interactions. Some responses are predictable, while others are more stochastic. While in vitro the outcome of stimulating a single type of cell may be stereotyped and reproducible, in vivo this is often not the case. This phenomenon often merits the use of animal models in predicting the impact of immunosuppressant drugs. A heavy burden of responsibility lies on the shoulders of the investigator when using animal models to study immunosuppressive agents. The principles of the three R׳s: refine (less suffering,), reduce (lower animal numbers) and replace (alternative in vitro assays) must be applied, as described elsewhere in this issue. Well designed animal model experiments have allowed us to develop all the immunosuppressive agents currently available for treating autoimmune disease and transplant recipients. In this review, we examine the common animal models used in developing immunosuppressive agents, focusing on drugs used in transplant surgery. Autoimmune diseases, such as multiple sclerosis, are covered elsewhere in this issue. We look at the utility and limitations of small and large animal models in measuring potency and toxicity of immunosuppressive therapies.

Original languageEnglish
Pages (from-to)295-302
Number of pages8
JournalEuropean Journal of Pharmacology
Early online date24 Mar 2015
Publication statusPublished - 15 Jul 2015


Dive into the research topics of 'The utility of animal models in developing immunosuppressive agents'. Together they form a unique fingerprint.

Cite this